-
Inotuzumab ozogamicin, sold
under the
brand name Besponsa, is an antibody-drug
conjugate medication used to
treat relapsed or
refractory B-cell precursor...
-
Gemtuzumab ozogamicin, sold
under the
brand name Mylotarg®, is an antibody-drug
conjugate (a drug-linked
monoclonal antibody) that is used to
treat acute...
- The term
ozogamicin in the
names of
monoclonal antibodies or antibody-drug
conjugates indicates that they are
linked to a
cytotoxic agent from the class...
-
expression is
known to be tied to TREM2. CD33 is the
target of
gemtuzumab ozogamicin (trade name: Mylotarg®; Pfizer/Wyeth-Ayerst Laboratories), an antibody-drug...
- to
their targeting properties. In 2001 Pfizer/Wyeth's drug
Gemtuzumab ozogamicin (trade name: Mylotarg) was
approved based on a
study with a surrogate...
-
Ozogamicin:
Reintroduction Based on
Favorable Risk:Benefit Profile". ADCReview.
September 2, 2017.
Retrieved August 14, 2024. "Gemtuzumab
Ozogamicin (Mylotarg®)...
- the
differentiating promyelocytes. The
monoclonal antibody,
gemtuzumab ozogamicin, has been used
successfully as a
treatment for APL,
although it has been...
- (AML). A
second calicheamicin-linked
monoclonal antibody,
inotuzumab ozogamicin (marketed as Besponsa), an anti-CD22-directed antibody-drug conjugate...
- Tositumomab), CD30 (Brentuximab), CD52 (Alemtuzumab) myeloid: CD33 (Gemtuzumab
ozogamicin)
Other Amivantamab Atezolizumab (+hyaluronidase)
Avelumab Axatilimab Belantamab...
-
Rituximab L01FA02
Ofatumumab L01FA03
Obinutuzumab L01FB01
Inotuzumab ozogamicin L01FB02
Moxetumomab pasudotox L01FC01
Daratumumab L01FC02
Isatuximab L01FD01...
